中国中西医结合肾病杂志
中國中西醫結閤腎病雜誌
중국중서의결합신병잡지
CHINESE JOURNAL OF INTEGRATED TRADITIONAL AND WESTERN NEPHROLOGY
2014年
4期
329-332
,共4页
王琳%李诗卉%张先闻%张春崧%李交%赵思宇%邓跃毅%田建辉%钱敏平%万林%陈以平
王琳%李詩卉%張先聞%張春崧%李交%趙思宇%鄧躍毅%田建輝%錢敏平%萬林%陳以平
왕림%리시훼%장선문%장춘숭%리교%조사우%산약의%전건휘%전민평%만림%진이평
特发膜性肾病%全基因组拷贝数变异%参芪膜肾方
特髮膜性腎病%全基因組拷貝數變異%參芪膜腎方
특발막성신병%전기인조고패수변이%삼기막신방
Idiopathic Membranous Nephropathy%Genome copy number variation%Shenqi moshen recipe
目的：探索特发膜性肾病患者全基因组拷贝数变异与参芪膜肾方疗效的关系。方法：选取80例经参芪膜肾方或经典的激素联合环磷酰胺方案治疗后完全缓解和无效的IMN病例,分为中药有效组(36例)、中药无效组(11例)、西药有效组(18例)和西药无效组(15例)。提取外周血基因组DNA并应用Affymetrix Genome-Wide Human SNP Array 6.0芯片检测全基因组基因拷贝数,应用CNVhac软件进行拷贝数变异( CNV)分析。结果：中药有效组与中药无效组在第5、第6及第8染色体上检测到的CNVs差异具有统计学意义(P<0.05)。其中位于6号染色体上的HLA族基因在中药有效组多数病例中表现为拷贝数扩增,而中药无效组的多数病例则表现为拷贝数缺失。西药有效组与西药无效组之间未检测到具有统计学差异的CNVs。结论：基因背景差异可能是导致参芪膜肾方取得不同疗效的基因水平机制,HLA的同族基因拷贝数变异影响参芪膜肾方疗效的发挥,前者有望成为该方治疗IMN的疗效预测因子,值得进一步深入研究。
目的：探索特髮膜性腎病患者全基因組拷貝數變異與參芪膜腎方療效的關繫。方法：選取80例經參芪膜腎方或經典的激素聯閤環燐酰胺方案治療後完全緩解和無效的IMN病例,分為中藥有效組(36例)、中藥無效組(11例)、西藥有效組(18例)和西藥無效組(15例)。提取外週血基因組DNA併應用Affymetrix Genome-Wide Human SNP Array 6.0芯片檢測全基因組基因拷貝數,應用CNVhac軟件進行拷貝數變異( CNV)分析。結果：中藥有效組與中藥無效組在第5、第6及第8染色體上檢測到的CNVs差異具有統計學意義(P<0.05)。其中位于6號染色體上的HLA族基因在中藥有效組多數病例中錶現為拷貝數擴增,而中藥無效組的多數病例則錶現為拷貝數缺失。西藥有效組與西藥無效組之間未檢測到具有統計學差異的CNVs。結論：基因揹景差異可能是導緻參芪膜腎方取得不同療效的基因水平機製,HLA的同族基因拷貝數變異影響參芪膜腎方療效的髮揮,前者有望成為該方治療IMN的療效預測因子,值得進一步深入研究。
목적：탐색특발막성신병환자전기인조고패수변이여삼기막신방료효적관계。방법：선취80례경삼기막신방혹경전적격소연합배린선알방안치료후완전완해화무효적IMN병례,분위중약유효조(36례)、중약무효조(11례)、서약유효조(18례)화서약무효조(15례)。제취외주혈기인조DNA병응용Affymetrix Genome-Wide Human SNP Array 6.0심편검측전기인조기인고패수,응용CNVhac연건진행고패수변이( CNV)분석。결과：중약유효조여중약무효조재제5、제6급제8염색체상검측도적CNVs차이구유통계학의의(P<0.05)。기중위우6호염색체상적HLA족기인재중약유효조다수병례중표현위고패수확증,이중약무효조적다수병례칙표현위고패수결실。서약유효조여서약무효조지간미검측도구유통계학차이적CNVs。결론：기인배경차이가능시도치삼기막신방취득불동료효적기인수평궤제,HLA적동족기인고패수변이영향삼기막신방료효적발휘,전자유망성위해방치료IMN적료효예측인자,치득진일보심입연구。
Objective:To explore the correlation between Genome Copy Number Variation ( CNV) of the patients of idio-pathic membranous nephropathy (IMN) and the clinical response of ShenQi MoShen Recipe (SQMSR). Methods:Eighty patients were divided into four groups according to the treatment and outcomes:the complete remission ( CR) group of SQMSR was indicated as the TCR group (36 cases);the no remission (NR) group of SQMSR as the TNR group (11 cases);the CR group of the immuno-suppressive agent (IA) as the ICR group (18 cases);the NR group of IA as the INR group (15 cases). Genomic DNA from periph-eral blood was extracted and genotyped with the Affymetrix Genenome-Wide Human SNP Array 6. 0. CNV analysis was performed on the raw data by the software of CNVhac. Results:The most significant CNVs regions among groups were located on chromosome 5, 6 and 8, on which patients of TCR group showed no loss while patients of TNR group showed loss (P<0. 05). The CNV of HLA gene family which located on chromosome 6 showed amplification on patients of TCR group, but loss on patients of TNR group. However, there were no significant CNVs between ICR and INR group. Conclusion:The differences in genetic background of IMN patients might be the cause of different clinical response of SQMSR. The CNVs of HLA gene family could become the predictive factor of the treat-ment of SQMSR and be worthy of further study.
